Israeli novel drug delivery system on the way to FDA approval, the company says


A company based on technology developed at the Hebrew University has now developed a series of patents that will allow the world to use certain drugs that have either not been highly effective or not safe by improving their administration.

Prof. Nissim Garti, who founded Lyotrope Delivery Systems (LDS) back in 2013, said The Jerusalem Post that his company recently signed several new global contracts and that its delivery system is now being tested in a number of preclinical and clinical studies. He expects at least one bioactive substance to be approved by the American Food and Drug Administration within two or three years.

LDS developed new molecular nanostructures for an improved and controlled delivery of soluble and insoluble active molecules. The word “lyotrop” is a word that connects the sounds and meanings of two others: lyo means “to dissolve” and tropic means “to change”.

Garti, who serves as CEO of the company, served in his role at the Hebrew University for more than 40 years. He was the director of the school’s Casali Institute of Applied Chemistry and a consultant to global companies in the region before starting his own. He is also the recipient of the Rockefeller Foundation Award and was a member of the search committee for the Nobel Prize in Chemistry. Prof. Nissim Garti. (Courtesy)

He said that post that LDS, in contrast to most delivery technologies based on solid particles or liquid formations, “offers a novel approach based on molecular architectures, which has been developed and constructed with unique computational mathematical simulation programs, taking into account the interface phenomena, the optimal surface, the release pattern of the active molecule as well as additional parameters to put together the liquid structures of LDS ”, it says on the company website.

The technology can be used for a wide variety of applications including oral, dermal, nasal, parenteral, ocular, and more.

Garti was the one who discovered that nanodroplets are able to capture active ingredients such as drugs at their interface rather than in the core of the droplet. He made the first discovery during his time at HU and later developed it further through LDS.

The platform enables innovative and generic drugs that would be insoluble in water and therefore not bioavailable to be transferred across cell membranes, which in most cases is impossible. The drugs remain intact until – if taken orally – they are released to the right place in the body when needed. Once the carrier is depleted of the medicament being carried, it is removed from the body through the feces.

Since the carriers can be completely diluted with water and are not influenced by the pH of the stomach, they do not cause any problems in the digestive tract.

In January, LDS announced a clinical trial and collaboration with a U.S. company, ANANDA, to evaluate the efficacy of cannabidiol using delivery technology to treat symptoms of post-traumatic stress disorder and neurocognitive impairment in patients with PTSD and PTSD comorbid with traumatic brain injury .

ANANDA licensed the structure for the study from LDS.

Garti’s company is also working on a new type of nail fungus treatment.

LDS is developing a thin, transparent, flexible, self-adhesive film in which drug molecules are embedded in nanodroplets. The textured film stops infection from spreading through the controlled release of therapeutics, which Garti says results in better performance and a better user experience.

“Nail fungus is basically incurable,” he told the post“Despite the many devices and applications that aim to handle it. We can get the drug through the nail – not around it, but through it. We have proof that it works, and we’re close to clinical trials here too. “

Source link


Leave A Reply